Kate F. Byth

1.6k total citations
20 papers, 1.0k citations indexed

About

Kate F. Byth is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Kate F. Byth has authored 20 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Cell Biology. Recurrent topics in Kate F. Byth's work include Microtubule and mitosis dynamics (7 papers), Cancer-related Molecular Pathways (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Kate F. Byth is often cited by papers focused on Microtubule and mitosis dynamics (7 papers), Cancer-related Molecular Pathways (7 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Kate F. Byth collaborates with scholars based in United States, United Kingdom and France. Kate F. Byth's co-authors include Stephen Green, Andrew P. Thomas, Robert W. Wilkinson, Janet D. Culshaw, Geoffrey I. Shapiro, Dongpo Cai, Catherine Geh, Claire Crafter, Nigel Barrass and Nicholas Keen and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kate F. Byth

20 papers receiving 998 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kate F. Byth United States	15	520	400	281	228	152	20	1.0k
Murray J. Towle United States	17	440 0.8×	509 1.3×	162 0.6×	211 0.9×	119 0.8×	24	1.1k
Timothy J. Guzi United States	16	792 1.5×	538 1.3×	160 0.6×	261 1.1×	127 0.8×	31	1.4k
Derek Wiswell United States	11	522 1.0×	459 1.1×	132 0.5×	151 0.7×	63 0.4×	14	934
Peter Drueckes Switzerland	15	727 1.4×	290 0.7×	86 0.3×	173 0.8×	96 0.6×	24	1.2k
Vito Guagnano Switzerland	16	896 1.7×	380 0.9×	112 0.4×	343 1.5×	86 0.6×	30	1.4k
Fleur M. Ferguson United States	16	1.3k 2.6×	394 1.0×	132 0.5×	210 0.9×	70 0.5×	33	1.7k
Vassilios Bavetsias United Kingdom	21	1.0k 2.0×	471 1.2×	447 1.6×	597 2.6×	117 0.8×	54	1.7k
Jonas Cicenas Switzerland	17	921 1.8×	684 1.7×	174 0.6×	108 0.5×	383 2.5×	28	1.5k
Johannes Bange Germany	10	966 1.9×	420 1.1×	100 0.4×	102 0.4×	211 1.4×	17	1.4k
Mathew P. Martin United Kingdom	19	1.1k 2.2×	499 1.2×	277 1.0×	311 1.4×	68 0.4×	35	1.6k

Countries citing papers authored by Kate F. Byth

Since Specialization

Citations

This map shows the geographic impact of Kate F. Byth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate F. Byth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate F. Byth more than expected).

Fields of papers citing papers by Kate F. Byth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate F. Byth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate F. Byth. The network helps show where Kate F. Byth may publish in the future.

Co-authorship network of co-authors of Kate F. Byth

This figure shows the co-authorship network connecting the top 25 collaborators of Kate F. Byth. A scholar is included among the top collaborators of Kate F. Byth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate F. Byth. Kate F. Byth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Torres, Sandra, Maximilian Joseph Brol, Fernando Magdaleno, et al.. (2021). The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis. Frontiers in Molecular Biosciences. 8. 715765–715765. 22 indexed citations

Curtis, Nicola J., Lorraine Mooney, Filippos Michopoulos, et al.. (2017). Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity. Oncotarget. 8(41). 69219–69236. 121 indexed citations

Greenawalt, Danielle, Winnie S. Liang, Sakina Saif, et al.. (2017). Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum. Oncotarget. 8(59). 99237–99244. 17 indexed citations

Ezell, Scott A., Suping Wang, Teeru Bihani, et al.. (2016). Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 7(8). 9163–9174. 26 indexed citations

Hennessy, Edward J., Gurmit Grewal, Kate F. Byth, et al.. (2015). Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists. Bioorganic & Medicinal Chemistry Letters. 25(10). 2041–2045. 2 indexed citations

Hennessy, Edward J., Vibha Oza, Ammar Adam, et al.. (2015). Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. Journal of Medicinal Chemistry. 58(17). 7057–7075. 19 indexed citations

Varnes, Jeffrey, Thomas W. Gero, Shan Huang, et al.. (2014). Towards the next generation of dual Bcl-2/Bcl-xL inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(14). 3026–3033. 14 indexed citations

Ezell, Scott A., Michele Mayo, Teeru Bihani, et al.. (2014). Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget. 5(13). 4990–5001. 41 indexed citations

Adam, Ammar, Kate F. Byth, Alwin G. Schuller, et al.. (2014). A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model. Blood. 124(21). 5304–5304. 4 indexed citations

10.

Buglio, Daniela, Sangeetha Palakurthi, Kate F. Byth, et al.. (2012). Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 120(2). 347–355. 50 indexed citations

11.

Zhang, Yue, Julie Parmentier, Zhongwu Lai, et al.. (2012). Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma. Blood. 120(21). 3720–3720. 2 indexed citations

12.

Buglio, Daniela, Francisco Vega, Sattva S. Neelapu, et al.. (2010). Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma. Blood. 116(21). 2852–2852. 2 indexed citations

13.

Byth, Kate F., Andrew P. Thomas, Gareth Hughes, et al.. (2009). AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Molecular Cancer Therapeutics. 8(7). 1856–1866. 104 indexed citations

14.

Jones, Clifford D., David Andrews, Andrew Barker, et al.. (2008). Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(24). 6486–6489. 29 indexed citations

15.

Wilkinson, Robert W., Rajesh Odedra, Simon P. Heaton, et al.. (2007). AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis. Clinical Cancer Research. 13(12). 3682–3688. 278 indexed citations

16.

Camidge, D. Ross, M. N. Pemberton, Jim Growcott, et al.. (2006). A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemotherapy and Pharmacology. 60(4). 479–488. 21 indexed citations

17.

Cai, Dongpo, Kate F. Byth, & Geoffrey I. Shapiro. (2006). AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9. Cancer Research. 66(1). 435–444. 65 indexed citations

18.

Byth, Kate F., et al.. (2006). The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. Molecular Cancer Therapeutics. 5(3). 655–664. 41 indexed citations

19.

Byth, Kate F., et al.. (2004). Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(9). 2245–2248. 95 indexed citations

20.

Byth, Kate F., Nicola J. Cooper, Janet D. Culshaw, et al.. (2004). Imidazo[1,2- b ]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(9). 2249–2252. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact